These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
55 related articles for article (PubMed ID: 11366517)
1. HIV antiretroviral agents. Gallant JE Posit Aware; 1999; 10(1):25. PubMed ID: 11366517 [TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
4. Drug Guide 2000: the antiretroviral agents. Gallant JE Posit Aware; 2000; 11(1):30-1. PubMed ID: 11366347 [TBL] [Abstract][Full Text] [Related]
5. AIDS practice issues today: interview with Paul Bellman, M.D. Interview by John S. James. Bellman P AIDS Treat News; 2000 Apr; (No 340):1-6. PubMed ID: 11367198 [TBL] [Abstract][Full Text] [Related]
6. Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation. Zaccarelli M; Perno CF; Forbici F; Cingolani A; Liuzzi G; Bertoli A; Trotta MP; Bellocchi MC; Di Giambenedetto S; Tozzi V; Gori C; D'Arrigo R; De Longis P; Noto P; Girardi E; De Luca A; Antinori A Antivir Ther; 2003 Feb; 8(1):51-6. PubMed ID: 12713064 [TBL] [Abstract][Full Text] [Related]
7. AIDS in the Third World: how to stop the HIV infection? De Clercq E Verh K Acad Geneeskd Belg; 2007; 69(2):65-80. PubMed ID: 17550059 [TBL] [Abstract][Full Text] [Related]
8. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine. Sproat M; Pozniak AL; Peeters M; Winters B; Hoetelmans R; Graham NM; Gazzard BG Antivir Ther; 2005; 10(2):357-61. PubMed ID: 15865231 [TBL] [Abstract][Full Text] [Related]
9. Long-Term suppression of HIV infection: benefits and limitations of current treatment options. Sension MG J Assoc Nurses AIDS Care; 2007; 18(1 Suppl):S2-10. PubMed ID: 17275719 [TBL] [Abstract][Full Text] [Related]
10. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420 [TBL] [Abstract][Full Text] [Related]
11. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire. Adjé-Touré CA; Cheingsong R; Garcìa-Lerma JG; Eholié S; Borget MY; Bouchez JM; Otten RA; Maurice C; Sassan-Morokro M; Ekpini RE; Nolan M; Chorba T; Heneine W; Nkengasong JN AIDS; 2003 Jul; 17 Suppl 3():S49-54. PubMed ID: 14565609 [TBL] [Abstract][Full Text] [Related]
13. Genotypic resistance tests in the management of the HIV-infected patient at virological failure. Aceti A; Carosi G Scand J Infect Dis Suppl; 2003; 106():61-6. PubMed ID: 15000587 [TBL] [Abstract][Full Text] [Related]
14. HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations. Wilson LE; Gallant JE Clin Infect Dis; 2009 Jan; 48(2):214-21. PubMed ID: 19072245 [TBL] [Abstract][Full Text] [Related]
15. Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir. Trotta MP; Bonfigli S; Ceccherini-Silberstein F; Bellagamba R; D'Arrigo R; Soldani F; Zaccarelli M; Concetta Bellocchi M; Lorenzini P; Marconi P; Boumis E; Forbici F; Comandini UV; Tozzi V; Narciso P; Federico Perno C; Antinori A J Med Virol; 2006 May; 78(5):535-41. PubMed ID: 16555278 [TBL] [Abstract][Full Text] [Related]
16. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients. Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104 [TBL] [Abstract][Full Text] [Related]
17. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients. Napravnik S; Keys JR; Quinlivan EB; Wohl DA; Mikeal OV; Eron JJ AIDS; 2007 Apr; 21(7):825-34. PubMed ID: 17415037 [TBL] [Abstract][Full Text] [Related]
18. Strategies for improving patient adherence to therapy and long-term patient outcomes. Battaglioli-DeNero AM J Assoc Nurses AIDS Care; 2007; 18(1 Suppl):S17-22. PubMed ID: 17275718 [TBL] [Abstract][Full Text] [Related]
19. The truth about HIV therapy. Learned J Posit Aware; 1999; 10(1):26. PubMed ID: 11366518 [TBL] [Abstract][Full Text] [Related]